MedTrace Logo

Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers

NCT05105243 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-11-04

Study results available
· View outcomes & findings →

Summary

Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.

Conditions

  • Safety Issues
  • Tolerance

Interventions

DRUG

CVN766

highly selective orexin-1 receptor (Ox1R) antagonist

Sponsors & Collaborators

  • Cerevance

    lead INDUSTRY

Principal Investigators

  • Ottavio Vitolo, MD · Cerevance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2022-10-30
Completion
2022-11-21

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05105243 on ClinicalTrials.gov